ReviewCancers2021
Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Nodal Marginal Zone Lymphoma with Prominent Expansion of PD-1+ T-Follicular Helper Cells: A Persistent Diagnostic Challenge with a Heterogeneous Mutational Architecture.International journal of molecular sciences · 2025Article
- Goodbye flat lymphoma biology.FEBS letters · 2025Review
- Development and validation of prognostic nomogram for overall survival in canine multicentric lymphoma: a retrospective study.BMC veterinary research · 2025Article
- Identification and Functional Investigation of Hub Genes Associated with Follicular Lymphoma.Biochemical genetics · 2025Article
- Increased STAT3 Phosphorylation in CD4Biomedicines · 2025Article
- Impact of the Immune Landscape in Follicular Lymphoma: Insights into Histological Transformation in the Rituximab Era.Cancers · 2024Article
- Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target.Blood cancer journal · 2024Article
- Unraveling the complexity of follicular lymphoma: insights and innovations.American journal of cancer research · 2024Review
- Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine.Journal for immunotherapy of cancer · 2023Article
- The pathobiology of follicular lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2023Article
- Advances in the multi-omics landscape of follicular lymphoma.International journal of biological sciences · 2023Review
- Tumor Microenvironment and Microvascular Density in Follicular Lymphoma.Journal of clinical medicine · 2022Article
- Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies.Frontiers in immunology · 2022Review
- Immunotherapies in Non-Hodgkin's Lymphoma.Cancers · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular Lymphoma (FL), the most common indolent non-Hodgkin's B cell lymphoma, is a paradigm of the immune microenvironment's contribution to disease onset, progression, and heterogeneity. Over the last few years, state-of-the-art technologies, including whole-exome sequencing, single-cell RNA sequencing, and mass cytometry, have precisely dissected the specific cellular phenotypes present in the FL microenvironment network and their role in the disease. In this already complex picture, the presence of recurring mutations, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.